
- Stock: In Stock
- Brand: Incepta Pharmaceuticals
- Product ID: insulin Glargine (rDNA)INN 100iu
100% Secure Payment
bKash | Nagad | Cards via SSLCommerz | COD
Monthly Medicines Available | Free Delivery on Eligible Orders
| Generic Name | Insulin Glargine (rDNA origin) |
| Brand Name | Vibrenta Penset |
| Manufacturer | Incepta Pharmaceuticals Ltd., Bangladesh |
| Dosage Form | Solution for Injection — Prefilled Pen (ConviPen) |
| Strength | 100 IU/mL |
| Pack Size | 1 Prefilled Pen (3 mL) |
| Drug Class | Long-acting Human Insulin Analogue |
| Prescription Required | Yes — Rx Only |
| Onset / Peak / Duration | Onset 1–2 hrs / no pronounced peak / Duration up to 24 hours |
What is Vibrenta Penset?
Vibrenta Penset is a prefilled disposable pen containing Insulin Glargine, a long-acting human insulin analogue manufactured by Incepta Pharmaceuticals Ltd. It provides smooth, near-peakless basal insulin coverage for up to 24 hours with a single daily injection, offered in a convenient pen format that eliminates the need for separate syringes and vial handling.
Generic Name and Composition
Each mL of solution contains 100 IU of Insulin Glargine, produced using recombinant DNA technology.
Indications
- Type 1 diabetes mellitus, as part of a basal-bolus insulin regimen
- Type 2 diabetes mellitus requiring long-acting basal insulin, alone or combined with oral antidiabetic agents
How It Works — Mechanism of Action
Insulin glargine forms microprecipitates at the injection site after subcutaneous administration, which slowly release insulin into the bloodstream over an extended period. This provides a relatively flat, prolonged insulin profile that mimics basal (background) insulin secretion, lowering blood glucose by promoting peripheral glucose uptake and suppressing hepatic glucose production.
Dosage and Administration
- Dosage is individualized by a physician based on blood glucose monitoring and treatment goals.
- Administered once daily by subcutaneous injection, at the same time each day, using the pen's dial-a-dose mechanism.
- Inject into the abdomen, thigh, or upper arm, rotating injection sites to reduce the risk of lipodystrophy.
- Always attach a new, sterile pen needle before each injection and dispose of it safely afterward.
- Do not shake the pen — insulin glargine is a clear solution and does not require resuspension.
- Check the pen and remaining dose dial before injecting; discard if the solution appears cloudy, discolored, or contains particles.
Side Effects
Common: Hypoglycemia, injection site reactions (redness, swelling, itching), lipodystrophy with repeated injection at the same site.
Uncommon: Generalized allergic reactions (rash, urticaria), peripheral edema, transient visual disturbances when starting therapy.
Rare: Severe systemic hypersensitivity reactions, anaphylaxis.
Drug Interactions
May enhance hypoglycemia: Oral antidiabetics, ACE inhibitors, MAOIs, salicylates, alcohol.
May reduce insulin effect: Corticosteroids, thyroid hormones, oral contraceptives, thiazide diuretics, danazol.
May mask or alter hypoglycemia symptoms: Beta-blockers, clonidine.
Contraindications
- Known hypersensitivity to insulin glargine or any excipient
- Episodes of hypoglycemia
Pregnancy and Lactation
Insulin is a standard treatment for diabetes during pregnancy and breastfeeding. Dose requirements often change during pregnancy and lactation — use only under close medical supervision.
Precautions and Warnings
- Never share a Vibrenta Penset between patients, even with a new needle each time.
- Monitor blood glucose regularly, especially when changing dose, diet, activity level, or during illness.
- Use caution in patients with renal or hepatic impairment, as insulin requirements may be reduced.
- Carry a fast-acting source of sugar at all times in case of hypoglycemia.
- Do not switch between insulin brands or types without medical supervision.
Overdose
Overdose can cause hypoglycemia, with symptoms ranging from sweating, palpitations, tremor, and hunger to confusion, seizures, and loss of consciousness in severe cases. Mild episodes can be managed with oral glucose; severe or unconscious episodes require immediate medical attention, including intravenous glucose or glucagon administration.
Storage Instructions
- Store unused pens in a refrigerator at 2–8°C. Do not freeze.
- Once in use, the pen may be kept below 30°C (away from direct heat and light) for up to 4 weeks, then discarded even if insulin remains.
- Always keep the pen cap on when not in use to protect from light.
- Keep out of reach of children.
Frequently Asked Questions
Q1: How is the Vibrenta Penset different from the Vibrenta vial?
Both contain the same insulin glargine, but the Penset is a prefilled, dial-a-dose pen for added convenience and portability, while the vial requires a separate syringe.
Q2: Can I reuse a pen needle?
No — use a new, sterile pen needle for every injection to reduce infection risk and ensure accurate dosing.
Q3: What if I forget a dose?
Contact your physician for guidance; do not double the next dose without medical advice.
Q4: How is Vibrenta different from NPH insulins like Maxsulin N?
Vibrenta (insulin glargine) is a long-acting analogue with a smooth, near-peakless 24-hour profile, while Maxsulin N (NPH) is intermediate-acting with a more defined peak and shorter duration. Your physician will choose the option that best fits your treatment plan.
Medical Disclaimer
This product is available by prescription only (Rx). The information provided is for educational purposes and does not replace professional medical advice. Always consult a registered physician before starting, stopping, or changing any insulin therapy. DiabetesStore.com.bd is a licensed online pharmacy in Bangladesh.














